Bio-Rad Laboratories, Inc. (BIO)
- Previous Close
277.31 - Open
279.06 - Bid 282.33 x 3100
- Ask 282.62 x 3000
- Day's Range
277.79 - 286.01 - 52 Week Range
261.59 - 431.79 - Volume
230,324 - Avg. Volume
218,738 - Market Cap (intraday)
8.033B - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-10.69 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
377.80
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
www.bio-rad.comRecent News: BIO
Performance Overview: BIO
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIO
Valuation Measures
Market Cap
8.03B
Enterprise Value
7.79B
Trailing P/E
--
Forward P/E
25.91
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.13
Price/Book (mrq)
0.89
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.37%
Return on Assets (ttm)
1.62%
Return on Equity (ttm)
-3.43%
Revenue (ttm)
2.61B
Net Income Avi to Common (ttm)
-322.37M
Diluted EPS (ttm)
-10.69
Balance Sheet and Cash Flow
Total Cash (mrq)
1.65B
Total Debt/Equity (mrq)
13.26%
Levered Free Cash Flow (ttm)
209.61M
Research Analysis: BIO
Company Insights: BIO
BIO does not have Company Insights